No material stock-moving catalyst. Monitor upcoming clinical catalysts for TSHA-102 (Rett syndrome) for meaningful price action.
TSHA drugs
TSHA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $5.50entry
- T+1 · 5mo ago −1.27%α −1.50% · $5.43
- T+5 · 5mo ago +3.82%α +3.25% · $5.71
- T+20 · 4mo ago +16.00%α +14.14% · $6.38
- T+60 · 3mo ago +3.45%α −0.55% · $5.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Taysha Gene Therapies granted 714,700 RSUs and an option for 468,600 shares to four new employees under its 2023 Inducement Plan, with a $5.97 exercise price. This is a routine equity inducement grant for new hires, not a material operational or financial event.
Key Facts
- 714,700 RSUs and an option for 468,600 shares granted to four new employees on June 1, 2026
- Stock option exercise price set at $5.97, equal to the closing price on grant date
- RSUs vest in four equal annual installments; option vests 25% on first anniversary, then monthly over 36 months
- Grant made under the 2023 Inducement Plan per Nasdaq Listing Rule 5635(c)(4)
Financial Impact
Equity grant of 1,183,300 total shares (RSUs + option shares) represents approximately 0.7% of TSHA's 1.7B market cap, but no cash impact; routine inducement for new hires.
Risk Factors
- Minimal dilution from equity grants, but not material to valuation
- No operational or financial update provided
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307344 |
Track record
14 reports on TSHA
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
- Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
- Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
- Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
- Jun 5, 202623w ago Press Release Neutral 2/10 Viewing Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
- May 6, 202627w ago 8-K Neutral 5/10 No price data
- May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
- Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers